IC
LCTX icon

IEQ Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

IEQ Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,447
Closed -$39.2K – 1997
2025
Q4 		$39.2K Sell
23,447
-136,966
-85% -$237K ﹤0.01% 1813
2025
Q3 		$271K Buy
160,413
+137,373
+596% +$163K ﹤0.01% 1563
2025
Q2 		$20.9K Buy
+23,040
New +$13.7K ﹤0.01% 1795

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IEQ Capital's LCTX Position: Q1 2026 in Review

IEQ Capital sold out of Lineage Cell Therapeutics (LCTX) in Q1 2026, closing a stake of 23,447 shares — an estimated $39.2K sold.

IEQ Capital first reported a position in LCTX in Q2 2025 and held it in 3 quarters. The position peaked at $271K in Q3 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • IEQ Capital reported no remaining Lineage Cell Therapeutics position as of Q1 2026 after selling out during the quarter.
  • IEQ Capital sold 23,447 Lineage Cell Therapeutics shares in Q1 2026, an estimated $39.2K.
  • IEQ Capital first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 3 quarters.
  • IEQ Capital's Lineage Cell Therapeutics position peaked at $271K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.